Fibroblast activation protein (FAP; also known as seprase) is a surface‐expressed proteolytic enzyme that has been identified as a promising immunotherapy target antigen for epithelial carcinomas such as prostate, lung and pancreatic cancer, and mesothelioma.13, 14, 15, 16, 17. This evidence concerns the gene FAP and familial pancreatic carcinoma.